Loading...
XSTO
BIOWKS
Market cap25mUSD
Oct 05, Last price  
3.09SEK
1D
-3.44%
1Q
-0.64%
IPO
-69.49%
Name

Bio-Works Technologies AB

Chart & performance

D1W1MN
XSTO:BIOWKS chart
P/E
—
P/S
4.09
EPS
—
Div yield, %
—
Shrs. gr., 5y
24.98%
Rev. gr., 5y
53.92%
Revenues
63m
+145.44%
1,542,0003,677,0004,945,0006,563,0005,573,0007,234,00021,910,00041,320,00043,896,00025,465,00062,502,000
Net income
-15m
L-59.19%
-12,361,000-17,157,000-23,657,000-37,955,000-42,113,000-44,549,000-12,942,000-44,950,000-56,821,000-37,357,000-15,247,000
CFO
-19m
L-56.42%
-13,123,000-14,457,000-21,232,000-34,689,000-40,041,000-43,359,000-13,369,000-39,880,000-58,990,000-43,168,000-18,811,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Bio-Works Technologies AB (publ) is a biotechnology company that specializes in the research, development, production, and distribution of agarose-based separation products. These sophisticated solutions are designed to facilitate the purification of proteins, peptides, and other biomolecules, with a primary focus on the Swedish market. Their comprehensive product portfolio encompasses items such as activated and affinity resins, BabyBio columns, immobilized metal-ion affinity chromatography (IMAC) resins, ion exchange resins, OptioBio glass columns, screening kits, and size exclusion chromatography (SEC) resins. These offerings find use across various applications, including those concerning antibodies, His-tagged proteins, other proteins, peptides, oligonucleotides, and in the purification of viruses and vaccine development. Established in 2006, the company is headquartered in Uppsala, Sweden.
URL
https://www.bio-works.com
IPO date
Dec 14, 2017
Employees
48
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
Virdings allé 18
Uppsala, C 754 50
SE
Address
Virdings alle 18
Uppsala, C 754 50
SE
Previous name
Goldcup 8869 AB

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT